MeSH D015212 - inflammatory bowel diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Salix Pharmaceuticals | Budesonide | Uceris | 2031-09-07 | 2013-01-14 |  |  |
| Teva | Budesonide, Formoterol | BiResp Spiromax |  | 2014-04-28 |  |  |
| Budesonide | Budesonide |  | 2008-11-18 |  |  | |
| Budesonide, Formoterol | Budesonide/Formoterol Teva |  | 2014-11-19 |  |  | |
| Budesonide, Formoterol | Budesonide/Formoterol Teva Pharma B.V |  | 2014-11-19 |  |  | |
| Budesonide, Formoterol | DuoResp Spiromax |  | 2014-04-28 |  |  | |
| Budesonide, Formoterol | Vylaer Spiromax |  | 2014-11-19 |  |  | |
| Padagis | Budesonide | Entocort |  | 2001-10-02 |  |  |
| Budesonide | Budesonide |  | 2023-04-12 |  |  | |
| Mylan | Budesonide, Formoterol | Breyna |  | 2022-03-15 |  |  |
| Budesonide | Budesonide |  | 2020-09-17 |  |  | |
| Johnson & Johnson | Budesonide | Rhinocort |  | 2015-03-23 |  |  |
| Cipla | Budesonide | Budesonide |  | 2017-11-16 |  |  |
| Lupin Research | Budesonide | Budesonide |  | 2018-11-09 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
51%18/35
Phase 2
36%16/44
Phase 3
33%9/27
Approved: 3Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use